What Happened? Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped in the afternoon session after UBS raised ...

Exponent (NASDAQ:EXPO) has had a rough three months with its share price down 15%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty ...

Fintel reports that on December 15, 2025, UBS maintained coverage of Exponent (NasdaqGS:EXPO) with a Neutral recommendation.

If you are wondering whether Exponent is a bargain or a trap at today’s price, you are not alone. This breakdown is designed to help you see what the market might be missing. The stock has slipped 1.6 ...

Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...

Earnings from consulting firm Exponent (NASDAQ: EXPO) came in below expectations, and the company continues to see challenges heading into 2024. Investors are moving to the sidelines, sending shares ...

Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund underperformed and generated a net ...

Exponent soars on impressive Q1 FY24 results, with sales surging 3.3% YoY to $144.933M, outperforming estimates. Engineering and scientific services dominate revenue, comprising 84% of Q1 earnings, ...

Exponent, Inc. will announce its Q4 and fiscal year 2024 results on February 6, 2025, followed by a conference call. Exponent, Inc. announced that it will release its financial results for the Fourth ...